|
10084
|
ERVEBO
|
Ebola
|
Hemorrhagic
|
Zaire ebolavirus
|
negative-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Merck & Co. Inc.
|
2019
|
USA
|
18 years and above
|
Single dose
|
Intramuscular
|
NA
|
Zaire Ebola virus glycoprotein
|
NA
|
US FDA, EMA
|
NA
|
NA
|
V920, rVSV-G-ZEBOV-GP, rVSV-ZEBOV
|
NA
|
NA
|
https://www.cdc.gov/vhf/ebola/clinicians/vaccine/index.html
|
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2817%2930313-4/fulltext
|
|
10085
|
Ad26.ZEBOV
|
Ebola
|
Hemorrhagic
|
Zaire ebolavirus
|
negative-sense, single-stranded RNA
|
Recombinant viral vector
|
Approved
|
Janssen Pharmaceutical
|
2020
|
USA
|
1 year and above
|
Single dose of Zabdeno on day 0 followed by 0.5mL dose of Mvabea post 8 week
|
Intramuscular
|
NA
|
Adenovirus type 26 encoding the Zaire ebolavirus, Mayinga variant glycoprotein
|
NA
|
US FDA, EMA
|
NA
|
NA
|
MVA-BN-Filo
|
NA
|
NCT02509494
|
https://clinicaltrials.gov/ct2/show/NCT02509494
|
https://clinicaltrials.gov/ct2/show/NCT05284097
|
|
10200
|
Ad5-EBOV
|
Ebola
|
Hemorrhagic
|
Zaire ebolavirus
|
negative-sense, single-stranded RNA
|
Non-replicating viral vector
|
Phase 1
|
National Institute of Health
|
2010
|
USA
|
18 - 50 years
|
NA
|
Intramuscular
|
NA
|
Ebola virus envelope glycoprotein
|
NA
|
NA
|
National Institute of Allergy and Infectious Diseases
|
NA
|
NA
|
27764560
|
NCT00374309
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287303/
|
https://www.precisionvaccinations.com/vaccines/ad5-ebov-ebola-vaccine#:~:text=CanSinBio%20Ad5%2DEBOV%20is%20an,type%2D5%20vector%20immune%20response.
|
|
10201
|
DNA
|
Ebola
|
Hemorrhagic
|
Zaire ebolavirus
|
negative-sense, single-stranded RNA
|
DNA based vaccine
|
Phase 1
|
National Institute of Health
|
2003
|
USA
|
18 - 44 years
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
National Institute of Allergy and Infectious Diseases
|
NA
|
NA
|
27764560
|
NCT00072605
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287303/
|
NA
|
|
10202
|
rVSV-EBOV
|
Ebola
|
Hemorrhagic
|
Zaire ebolavirus
|
negative-sense, single-stranded RNA
|
Recombinant viral vector
|
Phase 1
|
Merck & Co. Inc.
|
2014
|
USA
|
18 - 65 years
|
NA
|
Intramuscular
|
NA
|
Zaire Ebola virus glycoprotein
|
Vesicular Stomatitis Virus based
|
NA
|
National Institute of Allergy and Infectious Diseases
|
NA
|
NA
|
27764560
|
NCT02280408
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287303/
|
NA
|
|
10203
|
Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO)/ChAd3-EBO-Z
|
Ebola
|
Hemorrhagic
|
Zaire ebolavirus
|
negative-sense, single-stranded RNA
|
Recombinant viral vector
|
Phase 1
|
National Institute of Allergy and Infectious Diseases
|
2014
|
USA
|
18 - 65 years
|
NA
|
Intramuscular
|
NA
|
Wild type glycoproteins from Zaire and Sudan strains of Ebolavirus
|
Chimpanzee Adenovirus Vector expressing Zaire and sudan strain glycoprotein
|
NA
|
NA
|
NA
|
NA
|
27764560
|
NCT02231866
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287303/
|
NA
|
|
10204
|
HPIV3-EBO-Z ( HPIV3-EbovZ GP Vaccine)
|
Ebola
|
Hemorrhagic
|
Zaire ebolavirus
|
negative-sense, single-stranded RNA
|
Virus like particle
|
Phase 1
|
Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health
|
2015
|
USA
|
18 - 50 years
|
NA
|
Intranasal
|
NA
|
Zaire Ebola virus glycoprotein
|
Live-attenuated human Parainfluenza virus type 3 vectored vaccine expressing Ebolavirus Zaire glycoprotein
|
NA
|
National Institute of Allergy and Infectious Diseases
|
NA
|
NA
|
27764560
|
NCT02564575
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287303/
|
NA
|
|
10294
|
cAd3-EBO
|
Ebola
|
Hemorrhagic
|
Zaire ebolavirus
|
negative-sense, single-stranded RNA
|
Recombinant viral vector
|
Phase 2
|
Centre Hospitalier Universitaire Vaudois
|
2014
|
Switzerland
|
18 - 65 years
|
NA
|
Intramuscular
|
NA
|
Zaire Ebola virus glycoprotein
|
Chimpanzee Adenovirus Vector expressing Zaire strain glycoprotein
|
NA
|
NA
|
NA
|
NA
|
27764560
|
NCT02289027
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287303/
|
NA
|